<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815853</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCCGPS2</org_study_id>
    <nct_id>NCT01815853</nct_id>
  </id_info>
  <brief_title>Pre-operative Chemoradiotherapy or Chemotherapy Following Surgery and Adjuvent Chemotherapy in Patients With Gastric Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: It has been shown that the patitents with gastric cancer could benefits from
      peri-operative chemoradiotherapy, but whether the pre-operative chemoradiotherapy can improve
      patitents' outcome is still unclear.

      Patients and methods: In this study , patients with histologically confirmed gastric cancer
      whose pre-operative staging are cT4 any N,MO, aged from 18 to 70 years and with Eastern
      Cooperative Oncology Group performance status â‰¤2 and adequate organ function, are randomized
      1:1 to receive pre-operative chemoradiotherapy with DT45Gy/25f plus two cycles of
      XELOX(Xeloda 1000mg/m2, BID, DI-D14; Oxaliplatin 130mg/m2 on day 1;,21-days per cycle) or
      chemotherapy alone then following by surgical resection and adjuvant chemotherapy with XELOX
      at the same dose up to 4 cycles. The primary end point is overall survival (OS), and
      secondary end point is disease free survival(DFS) and safety. Final study analysis will be
      conducted in the end of the 5th year after the last patient's enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>radical resection rate</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-operative chemoradiotherapy arm:
Radiotherapy (45Grey/25F) + chemotherapy:(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles) then receive Surgical resection after surgery get post-operative chemotherapy with the same dose as pre-operative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-operative chemotherapy arm:
Chemotherapy:(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles) then receive Surgical resection after surgery get post-operative chemotherapy with the same dose as pre-operative</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pre-operative chemoradiotherapy</intervention_name>
    <description>Pre-operative chemoradiotherapy arm:
Radiotherapy (45Grey/25F) + chemotherapy(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles)</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine,Oxaliplatin</intervention_name>
    <description>chemotherapy:(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles)</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Capecitabine: Xeloda</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consensus of patients

          -  be able to receive oral administration

          -  from 18 to 70 years old

          -  be proven to be primary adenocarcinoma of gastric cancer and pre-operative staging
             cT4, any N,MO,

          -  without other chemotherapy and/or radiation against to the disease

          -  normal function of other organs including heart,liver ,kidney and so on

          -  Eastern Cooperative Oncology Group performance status:0~2

        Exclusion Criteria:

          -  history of other malignancy

          -  allergic reaction to xeloda or oxaliplatin

          -  be enrolling in other clinical trials

          -  abnormal GI tract function

          -  dysfunction of other organs

          -  female in pregnancy or lactation,or refuse to receive Contraception measures during
             chemotherapy

          -  other situation to be judged not adaptive to the study by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhi-wei Zhou, M.D,Ph.D</last_name>
    <phone>86-20-87343626</phone>
    <email>zhouzhw@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-wei Sun, MD</last_name>
      <phone>86-20-87343123</phone>
      <email>sunxw@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Zhi-wei Zhou, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <last_update_submitted>March 21, 2013</last_update_submitted>
  <last_update_submitted_qc>March 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhou Zhiwei</investigator_full_name>
    <investigator_title>Director of Gastric and Pancreatic Surgery</investigator_title>
  </responsible_party>
  <keyword>pre-operative,</keyword>
  <keyword>chemoradiotherapy,</keyword>
  <keyword>chemotherapy,</keyword>
  <keyword>treatment</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

